Dtsch Med Wochenschr 2011; 136(40): 2037-2039
DOI: 10.1055/s-0031-1286389
Verdauungs- und Stoffwechselkrankheiten | Commentary
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Pankreaserkrankungen – Update 2011

Pancreatic diseases: update 2011J. Ringel1 , M. M. Lerch1 , J. Mayerle1
  • 1Klinik für Innere Medizin A, Universitätsmedizin der Ernst-Moritz-Arndt-Universität, Greifswald
Further Information

Publication History

Publication Date:
28 September 2011 (online)

   Permissions and Reprints
Preview

Corrected by:

Pankreaserkrankungen – Update 2011Dtsch Med Wochenschr 2012; 137(05): 229-229
DOI: 10.1055/s-0031-1297282

Schlüsselwörter

pankreopriver Diabetes - Pankreaskarzinom - Autoimmunpankreatitis

Keywords

pancreatogenic diabetes - pancreatic cancer - autoimmune pancreatitis

Literatur

  • 1 Artinyan A, Anaya D A, McKenzie S. et al . Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.  Cancer. 2011;  117 2044-2049
    Search in Google Scholar
  • 2 Conroy T, Desseigne F, Ychou M. et al . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.  N Engl J Med. 2011;  364 1817-1825
    Search in Google Scholar
  • 3 Cui Y F, Andersen D K. Pancretogenic diabetes: Special considerations for management.  Pancreatology . 2011;  11 279-294
    Search in Google Scholar
  • 4 Elashoff M, Matveyenko A V, Gier B, Elashoff R, Butler P C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.  Gastroenterology. 2011;  141 150-156
    Search in Google Scholar
  • 5 Hsu C, Saif M. Diabetes and pancreatic cancer – highlights from the „2011 ASCO Annual Meeting“. Chicago, IL, USA; June 3 – 7,2011.  J Pancreas. 2011;  12 330-333
    Search in Google Scholar
  • 6 Moore M J, Goldstein D, Hamm J. et al . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2007;  25 1960-1966
    Search in Google Scholar
  • 7 Neoptolemos J P, Stocken D D, Bassi C. et al . Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.  JAMA. 2010;  304 1073-1081
    Search in Google Scholar
  • 8 Pelzer U, Schwaner I, Stieler J. et al . Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group.  Eur J Cancer. 2011;  47 1676-1681
    Search in Google Scholar
  • 9 Pisa A. The effect of time to adjuvant chemotherapy on survivial in nonmetastatic resectable pancreatic pancreatic cancer: A retrospective analysis.  J Clin Oncol. 2011;  29 (Suppl) e14519
    Search in Google Scholar
  • 10 Sahora K, Kuehrer I, Eisenhut A. et al . NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advavanced, nonmetastasized pancreatic cancer.  Surgery. 2011;  149 311-320
    Search in Google Scholar
  • 11 Shimosegawa T, Chari S T, Frukkoni L. et al . International consensus diagnostic criteria for autoimmune pancreatitis.  Pancreas. 2011;  40 352-358
    Search in Google Scholar

Prof. Dr. Markus M. Lerch

Klinik für Innere Medizin A
Universitätsmedizin
Ernst-Moritz-Arndt-Universität Greifswald

Friedrich-Loeffler-Str. 23a

17475 Greifswald

Phone: 03834/86-7230

Fax: 03834/86-7234

Email: lerch@uni-greifswald.de